source
- Novartis' RNA drug del-brax hits primary endpoint in early-stage FSHD trialNovartis reported that its antisense oligonucleotide conjugate, del-brax, achieved the primary biomarker endpoint in a Phase 1/2 study of patients with facioscapulohumeral muscular dystrophy (FSHD)…
- FDA grants emergency use authorization for generic Nitenpyram tablets to treat New World screwworm in dogs and catsThe U.S. Food and Drug Administration has issued an Emergency Use Authorization for generic Nitenpyram tablets to treat New World screwworm infestations in dogs, puppies, cats and kittens that weig…